Actavis PT Raised to $165.00 at Leerink Swann (ACT)
Equities researchers at Leerink Swann raised their price target on shares of Actavis (NYSE:ACT) to $165.00 in a research report issued on Tuesday, ARN reports. Leerink Swann’s target price suggests a potential upside of 14.58% from the company’s current price.
Actavis (NYSE:ACT) traded up 0.04% on Tuesday, hitting $144.06. 739,371 shares of the company’s stock traded hands. Actavis has a 52-week low of $81.73 and a 52-week high of $145.50. The stock’s 50-day moving average is $136.6 and its 200-day moving average is $120.8. The company’s market cap is $19.182 billion.
Actavis (NYSE:ACT) last posted its quarterly earnings results on Thursday, July 25th. The company reported $2.01 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.00 by $0.01. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.99 billion. The company’s quarterly revenue was up 46.8% on a year-over-year basis. Analysts expect that Actavis will post $8.34 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Actavis (NYSE:ACT) in a research note to investors on Wednesday, September 25th. They now have a $146.00 price target on the stock. Separately, analysts at Argus reiterated a “buy” rating on shares of Actavis (NYSE:ACT) in a research note to investors on Monday, September 16th. They now have a $150.00 price target on the stock. Finally, analysts at Barclays Capital raised their price target on shares of Actavis (NYSE:ACT) from $140.00 to $175.00 in a research note to investors on Monday, September 16th. They now have an “overweight” rating on the stock. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $144.50.
Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.